Core Insights - Equasens Group reported revenue of €172.2 million for the period ending September 30, 2025, reflecting an increase of 8.9% on a reported basis and 7.3% like-for-like compared to the same period in 2024 [3][4][23] Revenue Performance - Q3 2025 revenue was particularly strong, with a like-for-like growth of 9.4%, aligning with the Group's targets [4] - Total revenue for Q1, Q2, and Q3 of 2025 was €53.3 million, €54.7 million, and €50.2 million respectively, showing consistent growth across the quarters [2][4] Revenue by Business Segment - Systems and equipment segment saw a significant increase, contributing €69.1 million in 2025, up 13.1% from 2024 [6] - Maintenance and subscriptions segment grew to €77.9 million, a 6.2% increase, while software and services rose to €25.0 million, up 6.4% [6] - Q3 revenue breakdown showed systems and equipment at €22.1 million (+20.7%), maintenance and subscriptions at €26.5 million (+7.6%), and software and services at €7.6 million (+6.2%) [6] Division Performance - The Pharmagest Division reported revenue of €126.6 million, a 5.4% increase, with Q3 revenue at €40.7 million (+7.1%) [10][12] - Axigate Link Division revenue reached €25.3 million (+12.2%) with Q3 at €8.9 million (+23.8%) [16] - E-Connect Division saw substantial growth, reporting €11.4 million (+37.2%) and €3.9 million in Q3 (+38.3%) [18] Strategic Acquisitions and Innovations - Acquisitions contributed €2.4 million to revenue, with Calimed and Novaprove being significant contributors [5][8] - The Group's focus on innovation and European expansion has driven growth, particularly in France, Italy, and Germany [13][14][15] Future Outlook - The Group maintains its guidance for nearly 10% revenue growth on a reported basis for the second half of 2025 [23] - Continued focus on external growth opportunities to enhance service offerings and distribution networks is emphasized [23]

Core Insights - WallachBeth Capital LLC announced that Healthcare Triangle, Inc. has entered into warrant exercise agreements with accredited and institutional investors [1] Company Summary - Healthcare Triangle, Inc. is recognized as a leader in digital transformation solutions for the healthcare and life sciences sectors [1] - The company has agreed to exercise outstanding warrants to purchase a total of 377,702 shares of its common stock [1]

Core Insights - The company reported a revenue of €116.0 million for H1 2025, reflecting a 7.4% increase compared to H1 2024, with a like-for-like growth of 6.4% [6][3] - Recurring EBITDA reached €29.8 million, up 5.5% from the previous year, while the current operating profit increased by 1.2% to €21.1 million [6][3] - Net profit remained stable at €18.1 million, showing a slight increase of 0.3% [6][3] Financial Performance - Revenue breakdown shows growth across various divisions, with Pharmagest contributing €85.9 million (+4.7% like-for-like) and e-Connect showing significant growth of 36.6% to €7.5 million [7][16] - The recurring EBITDA margin slightly decreased to 25.7% from 26.1% in the previous year [4][6] - The net financial surplus increased by €19.2 million to €98.8 million, indicating a strong financial position [6][22] Division Highlights - **Pharmagest Division**: Stable current operating profit of €14.1 million, but a decrease in profit margin to 16.4% [8][9] - **Axigate Link Division**: Current operating profit remained stable at €4.4 million, with a margin decrease to 26.5% [13][15] - **e-Connect Division**: Current operating profit grew to €2.7 million, but the margin decreased to 36.0% [16][17] - **Medical Solutions Division**: Significant revenue growth of 29.1% to €5.1 million, with an improved margin of 6.7% [18][19] - **Fintech Division**: Experienced an operating loss of €0.3 million, with sales down 7.6% to €1.0 million [20] Strategic Developments - The company completed the acquisition of DIS and ResUrgences businesses, enhancing the Axigate Link Division's position in the public healthcare sector [23][24] - The estimated contribution of the acquired businesses to Group revenue is projected at 1.3% starting in Q3 2025 [25] - The company maintains its growth guidance of nearly 10% for H2 2025, driven by organic growth and contributions from recent acquisitions [26]

Core Insights - Equasens Group reported H1 2025 revenue of €116.0 million, reflecting a 7.4% increase on a reported basis and a 6.4% increase like-for-like compared to H1 2024 [3][4][12] Revenue Breakdown - Revenue from the Pharmagest Division was €85.9 million, up 4.7%, accounting for 74.1% of total revenue [9][10] - The Axigate Link Division reported revenue of €16.5 million, an increase of 6.7%, representing 14.2% of total revenue [10][11] - The e-Connect Division saw significant growth, with revenue of €7.5 million, up 36.6%, contributing 6.5% to total revenue [11] - The Medical Solutions Division generated €5.1 million in revenue, a 29.1% increase, with a 2.2% like-for-like growth [12] - The Fintech Division experienced a decline, with revenue of €1.0 million, down 7.6%, accounting for 0.9% of total revenue [15] Revenue by Activity Type - Configurations and hardware sales increased by 9.9% to €47.1 million, driven by strong performance in Pharmagest and e-Connect [7][8] - Maintenance and subscriptions grew by 5.5% to €51.4 million, benefiting from customer loyalty and SaaS offerings [8] - Software and services revenue rose by 6.4% to €17.4 million, supported by license sales and new deployments [8] Geographic Performance - In France, total business activities grew by 3.4% to €74.0 million, with notable growth in electronic labels and pharmacy automation solutions [13] - Italy saw a 16.5% increase in sales to €7.7 million, attributed to the opening of new pharmacies [13] - Germany's sales rose by 11.2% to €3.0 million, driven by medication adherence solutions [13] - Belgium confirmed a return to growth with a 6.4% increase to €1.2 million [13] Strategic Developments - The acquisition of CALIMED SAS contributed €1.1 million to the Medical Solutions Division's revenue [5] - On July 1, 2025, Equasens Group acquired Novaprove and DIS, enhancing the Axigate Link Division's offerings and adding over 300 public healthcare customers [16][17] - The integration of these acquisitions is expected to create synergies and strengthen the Group's position in the healthcare software market [21] Future Outlook - The Group anticipates continued growth in H2 2025, supported by positive commercial momentum across all divisions [18] - Investment efforts since 2024 are yielding results, with successful new software solutions being rolled out [20]